Écrit par MapLight | 04 Juin 2012

The U.S. House of Representatives passed its version of the FDA user fee bill ( H.R. 5651) Wednesday 387-5. The vote comes on the heels of the Senate’s 96-1 vote passing their version of the bill ( S. 3187) last week. The different bills would need to be reconciled in a conference committee and receive approval from both chambers before receiving President Obama's signature.

Given...

Écrit par GBI Research | 29 Mai 2012

NEW YORK (GBI Research), 29 May 2012 - Drug resistance and patent expiries are demanding that the antibacterial drug market moves forwards soon, but a current lack of interest from pharmaceutical companies has led to market stagnation, according to a new report by healthcare experts GBI Research.

The new report* shows that while hospital hygiene campaigns to conquer MRSA encourage...

Écrit par GlobalData | 18 Mai 2012

LONDON, UK (GlobalData), 18 May 2012 - The upcoming American Society of Clinical Oncology (ASCO) meeting is one of the most highly anticipated events in the world of cancer pharmaceuticals. This year’s 48th annual meeting will be held in Chicago from June 1-5, and investors and media outlets are already buzzing. The meeting abstracts released by ASCO on Wednesday, May 16 represent a...

Écrit par Didier Poli | 15 Mai 2012

Activité R&D accrue avec la préparation du lancement de la Phase IIb

Communication et activité scientifique intense en vue du congrès de l'EAACI

L'AP-HP, partenaire de DBV, présentera lors d'un late breaking abstract : "Six mois d'immunothérapie épicutanée dans l'allergie à l'arachide : innocuité et efficacité"

Nouveau brevet accordé aux Etats-Unis: Viaskin® est désormais le...